{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:07:10Z","timestamp":1792789630333,"version":"4.5.0"},"reference-count":23,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T00:00:00Z","timestamp":1473379200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["106491\/ Z\/14\/Z"],"award-info":[{"award-number":["106491\/ Z\/14\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["089275\/Z\/09\/Z"],"award-info":[{"award-number":["089275\/Z\/09\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004963","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["602525"],"award-info":[{"award-number":["602525"]}],"id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0162199","type":"journal-article","created":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T14:46:03Z","timestamp":1473432363000},"page":"e0162199","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":94,"title":["Experimental Treatment of Ebola Virus Disease with Brincidofovir"],"prefix":"10.1371","volume":"11","author":[{"given":"Jake","family":"Dunning","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick","family":"Antierens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Whitehead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iza","family":"Ciglenecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupa","family":"Kanapathipillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndsey","family":"Castle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Howell-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Pardinaz-Solis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Grove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trudie","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Olliaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"Horby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the RAPIDE-BCV trial team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,9,9]]},"reference":[{"key":"ref1","unstructured":"WHO. Categorization and prioritization of drugs for consideration for testing or use in patients infected with Ebola 2015. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/medicines\/ebola-treatment\/2015_0703TablesofEbolaDrugs.pdf?ua=1\" xlink:type=\"simple\">http:\/\/www.who.int\/medicines\/ebola-treatment\/2015_0703TablesofEbolaDrugs.pdf?ua=1<\/ext-link>."},{"key":"ref2","unstructured":"WHO. Potential Ebola therapies and vaccines 2014 [February 19 2016]. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/apps.who.int\/iris\/bitstream\/10665\/137590\/1\/WHO_EVD_HIS_EMP_14.1_eng.pdf?ua=1\" xlink:type=\"simple\">http:\/\/apps.who.int\/iris\/bitstream\/10665\/137590\/1\/WHO_EVD_HIS_EMP_14.1_eng.pdf?ua=1<\/ext-link>."},{"issue":"10","key":"ref3","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1586\/14787210.2014.948847","article-title":"Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses","volume":"12","author":"DF Florescu","year":"2014","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"8","key":"ref4","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1128\/AAC.49.8.3153-3162.2005","article-title":"Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate","volume":"49","author":"WC Magee","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"ref5","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.3390\/v2122740","article-title":"Development of CMX001 for the Treatment of Poxvirus Infections","volume":"2","author":"R Lanier","year":"2010","journal-title":"Viruses"},{"issue":"4","key":"ref6","doi-asserted-by":"crossref","first-page":"e1001815","DOI":"10.1371\/journal.pmed.1001815","article-title":"Evaluating clinical trial designs for investigational treatments of ebola virus disease","volume":"12","author":"BS Cooper","year":"2015","journal-title":"PLoS medicine"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.antiviral.2015.10.010","article-title":"The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus","volume":"125","author":"LK McMullan","year":"2016","journal-title":"Antiviral research"},{"issue":"5","key":"ref8","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1128\/AAC.05983-11","article-title":"First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses","volume":"56","author":"W Painter","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.antiviral.2015.02.007","article-title":"The efficacy and pharmacokinetics of brincidofovir for the treatment of lethal rabbitpox virus infection: a model of smallpox disease","volume":"117","author":"LC Trost","year":"2015","journal-title":"Antiviral research"},{"issue":"5","key":"ref10","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.bbmt.2011.09.007","article-title":"Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients","volume":"18","author":"DF Florescu","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref11","article-title":"The contribution of Ebola viral load at admission and other patient characteristics to mortality in a Medecins Sans Frontieres (MSF) Ebola Case Management Centre (CMC), Kailahun, Sierra Leone, June -October, 2014","author":"G Fitzpatrick","year":"2015","journal-title":"The Journal of infectious diseases"},{"issue":"12","key":"ref12","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/cid\/civ202","article-title":"Clinical predictors of mortality in patients with ebola virus disease","volume":"60","author":"M Barry","year":"2015","journal-title":"Clin Infect Dis"},{"key":"ref13","article-title":"Clinical Features of Patients With Ebola Virus Disease in Sierra Leone","author":"E Qin","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"1.5","key":"ref14","first-page":"S4","article-title":"High survival rates and associated factors among ebola virus disease patients hospitalized at donka national hospital, conakry, Guinea","volume":"8","author":"AI Qureshi","year":"2015","journal-title":"J Vasc Interv Neurol"},{"issue":"22","key":"ref15","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa1411680","article-title":"Clinical illness and outcomes in patients with Ebola in Sierra Leone","volume":"371","author":"JS Schieffelin","year":"2014","journal-title":"N Engl J Med"},{"issue":"13","key":"ref16","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation","volume":"369","author":"FM Marty","year":"2013","journal-title":"N Engl J Med"},{"key":"ref17","article-title":"The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States","author":"CS Kraft","year":"2015","journal-title":"Clin Infect Dis"},{"key":"ref18","article-title":"Characteristics and Clinical Management of a Cluster of 3 Patients With Ebola Virus Disease, Including the First Domestically Acquired Cases in the United States","author":"AM Liddell","year":"2015","journal-title":"Ann Intern Med"},{"issue":"22","key":"ref19","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMp1413084","article-title":"Ebola virus disease in West Africa\u2014clinical manifestations and management","volume":"371","author":"DS Chertow","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"ref20","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1056\/NEJMoa1409838","article-title":"Clinical care of two patients with Ebola virus disease in the United States","volume":"371","author":"GM Lyon","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa1411249","article-title":"Clinical presentation of patients with Ebola virus disease in Conakry, Guinea","volume":"372","author":"EI Bah","year":"2015","journal-title":"N Engl J Med"},{"key":"ref22","unstructured":"Chimerix I. Chimerix Focusing Efforts on CMV and Adenovirus Pivotal Trials 2015. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ir.chimerix.com\/releasedetail.cfm?releaseid=893927\" xlink:type=\"simple\">http:\/\/ir.chimerix.com\/releasedetail.cfm?releaseid=893927<\/ext-link>."},{"key":"ref23","article-title":"Administration of Brincidofovir and Convalescent Plasma in a Patient with Ebola Virus Disease","author":"DF Florescu","year":"2015","journal-title":"Clin Infect Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0162199","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T09:35:37Z","timestamp":1540028137000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0162199"}},"subtitle":[],"editor":[{"given":"John W","family":"Glod","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,9,9]]},"references-count":23,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2016,9,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0162199","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,9]]}}}